How quickly does ganirelix work?

As a GnRH receptor antagonist it suppresses LH and FSH within hours, without the delay caused by the initial flare of GnRH agonists.

Is ganirelix the same as cetrorelix?

Both are injectable GnRH antagonists with the same approved purpose in ART; a randomized comparison found them broadly comparable in preventing LH surges.

Does it lower the risk of ovarian hyperstimulation syndrome?

GnRH-antagonist protocols are generally associated with lower OHSS risk than agonist long protocols, but OHSS remains a risk of stimulation and requires monitoring.

Can I use ganirelix on my own?

No. It is a prescription drug administered within a supervised fertility protocol; timing depends on individual monitoring and must be directed by a clinician.

EMA-approvedaka Antagon, Orgalutran

Ganirelix — Complete Research Guide (2026)

Last updated 2026-06-30

TL;DR

Ganirelix (also known as Antagon) is a peptide catalogued under Sexual Health (GnRH antagonist). It is described as: GnRH receptor antagonist. Documented context: Assisted reproduction. Neutral reference entry; EU status: EU-approved prescription medicine.

What is Ganirelix?

Ganirelix (marketed as Orgalutran in Europe and Antagon in the US) is a synthetic decapeptide GnRH receptor antagonist, approved by the FDA and EMA to inhibit premature LH surges in women undergoing controlled ovarian stimulation for assisted reproduction.

Its human evidence base includes the pivotal dose-finding trial that established the standard dose and comparative randomized trials against the long GnRH-agonist protocol.

It is a physician-administered prescription drug, not a supplement.

How does Ganirelix work?

Ganirelix competitively occupies pituitary GnRH receptors, causing rapid, dose-dependent suppression of LH and FSH release.

As an antagonist it acts without the initial stimulatory flare of GnRH agonists, so gonadotropin suppression is essentially immediate rather than delayed by an initial surge.

What does the research say about Ganirelix?

Ganirelix produces immediate, dose-dependent LH suppression that prevents premature LH surges during ovarian stimulation, with the pivotal trial identifying the optimal daily dose. ^[1]
Compared with the long GnRH-agonist protocol, ganirelix is effective, safe, and streamlines treatment in a controlled multicentre randomized trial. ^[2]
Perinatal outcomes of pregnancies conceived in ganirelix-treated stimulation cycles were reassuring in a prospective randomized cohort. ^[3]

Clinical research & studies

The references below are the primary sources cited throughout this guide. Each links directly to PubMed or the regulator. Where evidence is preclinical (animal or in-vitro), that is stated rather than implied.

[1] A double-blind, randomized, dose-finding study to assess the efficacy of the gonadotrophin-releasing hormone antagonist ganirelix (Org 37462) to prevent premature luteinizing hormone surges in women undergoing ovarian stimulation with recombinant follicle stimulating hormone (Puregon) — Ganirelix Dose-finding Study Group, Human Reproduction 1998. (Double-blind dose-finding randomized controlled trial)
[2] Treatment with the gonadotrophin-releasing hormone antagonist ganirelix in women undergoing ovarian stimulation with recombinant follicle stimulating hormone is effective, safe and convenient: results of a controlled, randomized, multicentre trial. The European Orgalutran Study Group — Borm G et al., Human Reproduction 2000. (Multicentre randomized controlled trial (vs agonist long protocol))
[3] Perinatal outcome of pregnancy after GnRH antagonist (ganirelix) treatment during ovarian stimulation for conventional IVF or ICSI: a preliminary report — Olivennes F et al., Human Reproduction 2001. (Prospective randomized cohort (perinatal follow-up))
[4] Dynamics of the development of multiple follicles during ovarian stimulation for in vitro fertilization using recombinant follicle-stimulating hormone (Puregon) and various doses of the gonadotropin-releasing hormone antagonist ganirelix (Orgalutran/Antagon) — de Jong D et al., Fertility and Sterility 2001. (Randomized controlled trial)
[5] Treatment with the GnRH antagonist ganirelix prevents premature LH rises and luteinization in stimulated intrauterine insemination: results of a double-blind, placebo-controlled, multicentre trial — Lambalk CB et al., Human Reproduction 2006. (Double-blind placebo-controlled multicentre RCT)
[6] The gonadotrophin-releasing hormone antagonist ganirelix - history and introductory data — Out HJ et al., Human Fertility 2002. (Narrative review)

Dosing context

This is not medical advice or a usage recommendation. Dosing figures are reported research context only, cited from the published literature.

For context only: it is typically given as a small daily subcutaneous injection started in the mid-follicular phase and continued until the trigger, with timing guided by follicle and hormone monitoring.

Exact dose and schedule are set by a fertility clinician within a supervised cycle, not self-directed.

Side effects & safety profile

Ganirelix is generally well tolerated; the most frequently reported effect is a mild, transient injection-site skin reaction, and GnRH-antagonist protocols are associated with a lower risk of ovarian hyperstimulation syndrome than agonist long protocols.

It must be used only within a monitored ART cycle under specialist supervision; rare hypersensitivity reactions have been described, and it is contraindicated in pregnancy.

Stacking & combinations

It is used only alongside prescribed gonadotropins within a supervised stimulation protocol and is not intended for any non-medical combination use.

Finding Ganirelix vendors

This is an independent, neutral directory — we sell nothing and route no purchases. Use it to read regulatory context and (where available) genuine, moderated vendor information for your country.

Choose your country

We never list placeholder vendors. Pick your country to see neutral regulatory context.

Browse the directory

User reviews

No reviews yet

Reviews appear here once submitted and moderated. An aggregate rating is shown only after at least 5 genuine reviews — we never fabricate ratings.

Frequently asked questions

It is approved to inhibit premature LH surges in women undergoing controlled ovarian stimulation for assisted reproduction such as IVF or ICSI.

References

[1] A double-blind, randomized, dose-finding study to assess the efficacy of the gonadotrophin-releasing hormone antagonist ganirelix (Org 37462) to prevent premature luteinizing hormone surges in women undergoing ovarian stimulation with recombinant follicle stimulating hormone (Puregon) — Ganirelix Dose-finding Study Group, Human Reproduction 1998. PMID: 9853849. View sourceStudy: Double-blind dose-finding randomized controlled trialEstablished the daily dose of ganirelix that optimally prevents premature LH surges during stimulation.
[2] Treatment with the gonadotrophin-releasing hormone antagonist ganirelix in women undergoing ovarian stimulation with recombinant follicle stimulating hormone is effective, safe and convenient: results of a controlled, randomized, multicentre trial. The European Orgalutran Study Group — Borm G et al., Human Reproduction 2000. PMID: 10875855. View sourceStudy: Multicentre randomized controlled trial (vs agonist long protocol)Ganirelix was effective, safe, and convenient compared with the GnRH-agonist long protocol.
[3] Perinatal outcome of pregnancy after GnRH antagonist (ganirelix) treatment during ovarian stimulation for conventional IVF or ICSI: a preliminary report — Olivennes F et al., Human Reproduction 2001. PMID: 11473947. View sourceStudy: Prospective randomized cohort (perinatal follow-up)Perinatal outcomes after ganirelix-treated cycles were reassuring.
[4] Dynamics of the development of multiple follicles during ovarian stimulation for in vitro fertilization using recombinant follicle-stimulating hormone (Puregon) and various doses of the gonadotropin-releasing hormone antagonist ganirelix (Orgalutran/Antagon) — de Jong D et al., Fertility and Sterility 2001. PMID: 11287020. View sourceStudy: Randomized controlled trialCharacterized follicular dynamics across ganirelix doses during FSH stimulation.
[5] Treatment with the GnRH antagonist ganirelix prevents premature LH rises and luteinization in stimulated intrauterine insemination: results of a double-blind, placebo-controlled, multicentre trial — Lambalk CB et al., Human Reproduction 2006. PMID: 16361296. View sourceStudy: Double-blind placebo-controlled multicentre RCTGanirelix prevented premature LH rises and luteinization in stimulated IUI cycles.
[6] The gonadotrophin-releasing hormone antagonist ganirelix - history and introductory data — Out HJ et al., Human Fertility 2002. PMID: 11939160. View sourceStudy: Narrative reviewSummarizes the development and introductory clinical data for ganirelix.

This article is for educational and research purposes only. Peptides discussed here are not approved for human consumption by the FDA, EMA, or equivalent regulators outside of specific clinical contexts. Always consult a licensed medical professional before any therapeutic use.